1Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, et al. Mefformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 1501-1507.
2Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65-70.
3Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
4Kloting N, Berndt J, Kralisch S, Kovacs E Fasshauer M, Schon MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
5Gonzalez-Ortiz M, Martinez-Abundis E. Comparison of several formulas to assess insulin action in the fasting state with the hyperglycemic-hyperinsulinemic clamp technique in healthy individuals. Rev Invest Clin 2003; 55:419-422.
6Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X, et al. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008; 201: 378-384.
7World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complication. WHO/NCD/NCS 1999: 31-33. (Accessed at http://whqlibdoc. who. int/hq/1999/WHO_NCD_NCS_99. 2.pdj-').
8WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
9Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
10Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.
